טוען...
Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors are a novel group of hypolipidemic drugs that are recommended particularly for high-risk hypercholesterolemia patients, including those with primary hypercholesterolemia (PH), where lifelong exposure to high low-density lipoprotein (LD...
שמור ב:
| הוצא לאור ב: | Life (Basel) |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
MDPI
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8224623/ https://ncbi.nlm.nih.gov/pubmed/34071103 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/life11060466 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|